RxDoctor Payments Data

Megan Ogburn, PA

Physician Assistant · Mobile, ALNPI 1063719227

Payments from drug & device makers

$2,218in general payments, 2019–2025

Across 109 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$557
  • Amgen$236
  • Novartis$232
  • Boehringer Ingelheim$201
  • AstraZeneca$171
  • Cvrx, Inc.$160
  • plus $661 from 13 others

What the payments were for

  • Food & beverage$2,218100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,218 in reported general payments places this provider in the 75th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$20,577
Medicare patients
241
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$126,222
EntrestoSacubitril/Valsartan31$38,779
XareltoRivaroxaban36$26,293
JardianceEmpagliflozin20$25,510
Repatha SureclickEvolocumab22$12,160
Ranolazine ErRanolazine38$4,581
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$1,880
Atorvastatin Calcium108$1,306
Metoprolol Succinate85$1,106
Carvedilol121$1,080
ClopidogrelClopidogrel Bisulfate69$869
Losartan Potassium51$567
Amiodarone Hcl28$520
Amlodipine Besylate82$491
Furosemide107$486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$557$126,222134 claims
NovartisEntresto$232$38,77931 claims
Johnson & JohnsonXarelto$143$26,29336 claims
Boehringer IngelheimJardiance$201$25,51020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →